세계의 바이오의약품 수탁제조기관(CMO) 시장 : 기회와 전략(-2033년)
Biopharmaceutical Contract Manufacturing Organization (CMO) Global Market Opportunities And Strategies To 2033
상품코드 : 1478533
리서치사 : The Business Research Company
발행일 : 2024년 05월
페이지 정보 : 영문 277 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ₩ 7,161,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ₩ 10,741,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ₩ 14,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계 바이오의약품 수탁제조기관(CMO) 시장은 2018년 112억 8,280만 달러로 평가되었으며, 2023년까지 연평균 13.0% 이상 성장할 것으로 예상됩니다.

생명과학 분야 벤처캐피털 투자의 견고성 향상

생명과학 부문에 대한 벤처캐피털 투자가 꾸준히 증가하면서 바이오의약품 수탁제조기관(CMO) 시장의 성장을 견인했습니다. 생명과학 부문은 생물학 관련 연구개발을 수행하는 기업 및 조직을 의미합니다. 벤처캐피털 투자의 견고성은 모델, 테스트, 시스템의 매개변수 및 가정이 변경되었을 때 제대로 작동할 수 있는 능력을 나타내는 기능입니다. 생명과학 부문에 대한 투자가 증가하면 바이오의약품 제조도 증가할 것입니다. 예를 들어, 2021년 9월 미국 투자 컨설팅 전문회사 JLL에 따르면 영국은 지난 3개월 동안 역대 최대 규모의 벤처캐피털을 유치했으며, 2021년 6월 1일부터 8월 26일까지 19억 파운드가 조달되었습니다. 이 투자로 2021년 영국 전체 YTD(1년 누계)는 42억 5,000만 파운드(약 57억 8,700만 달러)로 2020년 28억 파운드에서 증가하였습니다. 따라서 생명과학 부문에 대한 벤처캐피털 투자의 견조한 증가는 바이오의약품 수탁제조기관(CMO) 시장의 성장을 뒷받침했습니다.

목차

제1장 주요 요약

제2장 목차

제3장 목차

제4장 표목차

제5장 보고서 구조

제6장 시장 특징

제7장 주요 시장 동향

제8장 바이오의약품 수탁제조기관(CMO) 시장 : 거시경제 시나리오

제9장 세계의 시장 규모와 성장

제10장 세계의 바이오의약품 수탁제조기관(CMO) 시장 : 세분화

제11장 바이오의약품 수탁제조기관(CMO) 시장 : 지역·국가별 분석

제12장 아시아태평양 시장

제13장 서유럽 시장

제14장 동유럽 시장

제15장 북미 시장

제16장 남미 시장

제17장 중동 시장

제18장 아프리카 시장

제19장 경쟁 상황과 기업 개요

제20장 경쟁 벤치마킹

제21장 경쟁 대시보드

제22장 주요 인수합병

제23장 기회와 전략

제24장 바이오의약품 수탁제조기관(CMO) 시장 : 결론과 제안

제25장 부록

ksm
영문 목차

영문목차

Biopharmaceutical contract manufacturing organization (CMO) is a company that provides manufacturing services to biopharmaceutical companies on a contractual basis. These organizations specialize in the production of biopharmaceutical products such as biologics, vaccines, gene therapies and other complex therapeutics.

The biopharmaceutical contract manufacturing organization (CMO) market consists of sales of outsourcing services provided by third-party companies for drug development and production in the biopharmaceutical industry. These organizations offer services such as cell line development, bioprocess development, formulation, analytical testing and antibody drug development.

The global biopharmaceutical contract manufacturing organization (CMO) market was valued at $11,282.8 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 13.0%.

Increase In The Robustness Of Venture Capital Investments For The Life Science Sector

The increase in the robustness of venture capital investments for the life science sector drove the growth of the biopharmaceutical contract manufacturing organization (CMO) market during the historic period. The life sciences sector refers to the businesses and organizations that conduct research and development on living beings. The robustness of venture capital investments is a feature describing the capacity of a model, test, or system to function correctly when its parameters or presumptions are changed. As the investment in the life science sector increases, there will be an increase in the manufacturing of biopharmaceuticals. For instance, in September 2021, according to JLL, a US-based company specializing in investment consultancy, the record amount of venture capital was raised in the UK over the last three months, with £1.9 billion raised between 1 June and 26 August 2021. This investment brings the UK total for 2021 to £4.25 billion ($5.787 billion) YTD (year to date), up from £2.8 billion in 2020. Therefore, the increase in the robustness of venture capital investments for the life science sector supported the biopharmaceutical contract manufacturing organization (CMO) market growth.

Strategic Partnerships and Collaborations Among Market Players To Drive Innovation

Strategic partnerships and collaborations are a key trend gaining popularity in the biopharmaceutical contract manufacturing organization (CMO) market. Major companies operating in the market are focusing on partnerships and collaborations to strengthen their position in the market. For example, in September 2023, Samsung Biologics, a South Korea-based biotechnology company, announced an expanded strategic agreement with Bristol Myers Squibb, a US-based biopharmaceutical company, to manufacture an antibody cancer drug substance. Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at the company's latest and largest biomanufacturing facility, Plant 4, South Korea. Further, in March 2022, TFF Pharmaceuticals, a US-based clinical-stage biopharma company and Catalent, a US-based provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products, announced a collaboration focused on the development of dry powder formulations of biologics for inhaled delivery using thin film freezing technology. The company collaborates with various CMOs, including those focused-on experimentation and addressing societal needs, to enhance treatment possibilities for patients suffering from a wide range of diseases, utilizing their unique technology.

The global biopharmaceutical contract manufacturing organization (CMO) market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 14.66% of the total market in 2022.

Biopharmaceutical Contract Manufacturing Organization (CMO) Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global biopharmaceutical contract manufacturing organization (CMO) market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Where is the largest and fastest-growing market for biopharmaceutical contract manufacturing organization (CMO)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The biopharmaceutical contract manufacturing organization (CMO) market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider biopharmaceutical contract manufacturing organization (CMO) market; and compares it with other markets.

The report covers the following chapters

Market Segmentation - Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by product, by source and by service in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.

Scope

Markets Covered:

Table of Contents

1 Executive Summary

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

7 Major Market Trends

8 Biopharmaceutical Contract Manufacturing Organization (CMO) Market - Macro Economic Scenario

9 Global Market Size and Growth

10 Global Biopharmaceutical Contract Manufacturing Organization (CMO) Market Segmentation

11 Biopharmaceutical Contract Manufacturing Organization (CMO) Market, Regional and Country Analysis

12 Asia-Pacific Market

13 Western Europe Market

14 Eastern Europe Market

15 North America Market

16 South America Market

17 Middle East Market

18 Africa Market

19 Competitive Landscape And Company Profiles

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

23 Opportunities And Strategies

24 Biopharmaceutical Contract Manufacturing Organization (CMO) Market, Conclusions And Recommendations

25 Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기